To Evaluate Oral Health and Quality of Life Associated With Use of a Denture Adhesive

August 12, 2021 updated by: GlaxoSmithKline

A Randomized, Single-blind, Efficacy Study to Evaluate Oral Health and Quality of Life Associated With Use of a Denture Adhesive

The aim of this study is to evaluate the use of a denture adhesive and its ability to demonstrate the improvement in overall gum-health and to improve the oral health related quality of life (OHrQoL) in participants who wear full dentures.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study will be a single center, controlled, single-blind, randomized, two-treatment, parallel design in healthy participants with a full conventional, acrylic denture in either or both dental arches, with a treatment period of 12 weeks. The study will assess the effectiveness of an experimental denture adhesive in the improvement of denture-bearing tissue irritation related measures, and the participant's oral health related quality of life. Participants will be randomized to one of the 2 treatment groups i.e. experimental denture arm group and control arm group and will undergo an oral soft tissue (OST) examination. Participants with satisfactory dentures, adequate retention and stability and who qualify all the inclusion and exclusion criteria will continue in the study. Participants will complete the Gum Comfort, OHIP-Edent questionnaires and GOHAI questionnaire. The assessments will be made at Baseline, and after 1, 4, 8 and 12 weeks treatment.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
119

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
      • Mississauga, Canada, L5N 6J2
        • GSK Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Participant provision of a signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study before any assessment is performed.
  2. A participant who is willing and able to comply with scheduled visits, treatment plan, and other study procedures.
  3. A participant in good general and mental health with, in the opinion of the investigator or medically qualified designee, no clinically significant/relevant abnormalities in medical history or upon oral examination, or condition, that would impact the participant's safety, wellbeing or the outcome of the study, if they were to participate in the study, or affect the individual's ability to understand and follow study procedures and requirements.
  4. Pregnant women: must agree to use a highly effective method of contraception throughout the study and for 5 days after the last dose of assigned treatment.

  5. Participant has denture prostheses that fulfill all of the following:

    1. A conventional acrylic full denture in either or both of the upper and lower arches. The full denture may be opposed by a partial denture, natural teeth or another full denture.
    2. Dentures are well fitting (Kapur (Olshan Modification) Retention and Stability Index Sum Score ≥ 3 for each denture [maxillary and/or mandibular] with no individual stability or retention scores <1.

    c Denture(s) are well made (according to the well-made assessment).

  6. Participant is a habitual wearer of their denture(s) defined as participants who wear their dentures for the majority of their time whilst awake.
  7. Participant has worn their full denture(s) for at least a year.
  8. Participant has not used any denture adhesive in the last year.
  9. Participant currently adopts acceptable denture cleansing habits and routine (a minimum would include daily brushing with a chemical cleaner such as toothpaste or soap, in addition to at least once a week soaking in commercial denture cleansing product). Unacceptable cleaning would include cleaning with water alone or using other non-specialized cleaning methods.

Exclusion Criteria:

  1. A participant who is an employee of the investigational site, either directly involved in the conduct of the study or a member of their immediate family; or an employee of the investigational site otherwise supervised by the investigator; or, a GlaxoSmithKline Consumer Healthcare (GSKCH) employee directly involved in the conduct of the study or a member of their immediate family.
  2. A participant who has participated in other studies (including non-medicinal studies) involving investigational product(s) within 30 days prior to study entry and/or during study participation.
  3. A participant with, in the opinion of the investigator or medically qualified designee, an acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator or medically qualified designee, would make the participant inappropriate for entry into this study.
  4. A participant who is a pregnant female.
  5. A participant who is a breastfeeding female.
  6. A participant with known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.
  7. A participant who, in the opinion of the investigator or medically qualified designee, should not participate in the study.

  8. A participant unwilling or unable to comply with the Lifestyle Considerations:

    1. Participants will not be permitted to have any dental/denture work performed during the time they are in the study, unless discussed and permitted by the examiner. This is to ensure that the denture fit will not be altered during the study.
    2. Participants will not be able to use any denture adhesive product other than that supplied by the investigator.
    3. Participants should continue using their usual denture cleansing methodology throughout the study.
  9. A participant who has previously been enrolled in this study.
  10. A participant who has had recent (within 30 days) gingival surgery.
  11. Taking or have taken a bisphosphonate drug (i.e. Fosamax, Actonel, Boniva).
  12. A participant with any clinically significant or relevant oral abnormality (e.g. temporomandibular joint problems) that, in the opinion of the investigator, could affect the Participant's participation in the study.
  13. A participant with any condition or medication which, in the opinion of the investigator, is currently causing xerostomia.
  14. A participant with recent history (within the last year) of alcohol or other substance abuse.
  15. A participant with OST examination findings such as stomatitis, open sores, lesions, or swelling which in the opinion of the investigator, would interfere with the conduct of the study. Mild, chronic conditions commonly expected from the use of dentures in the investigators opinion, are acceptable in this study.
  16. A participant who is using any medication that, in the opinion of the investigator, would interfere with the conduct of the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Experimental denture adhesive
In this arm, participants will apply the experimental adhesive on their dentures once per day when the denture is placed in mouth.
Drug: Experimental Denture Adhesive
In this arm, participants will apply the experimental adhesive on their dentures once per day when the denture is placed in mouth.
No Intervention: No adhesive
In this arm, participants will not use any denture adhesive.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Gum Health Analysis by Change From Baseline in Overall Mean Scores of Participant Responses to the Gum Comfort Questionnaire After 12 Weeks
Time Frame: At Baseline and after 12 weeks
Gum comfort questionnaire was referred to assess the gum health of the denture wearer and to compare the ability of an experimental denture adhesive to provide self-perceived mucosal benefits compared to the use of no adhesive after 12 weeks of product use. It was comprised of 5 questions- Q1: My gums feel comfortable when wearing my denture(s), Q2: I feel my gums are cushioned from the impact of chewing and biting; Q3: My gums do not feel sore at the end of the day; Q4: My gums are not irritated by trapped food particles under my denture(s); Q5: My gums do not feel tired at the end of the day. The participants recorded the response on scale of 0-4: 0-Agree Strongly, 1-Agree Somewhat, 2-Neither Agree or Disagree, 3-Disagree Somewhat, 4- Disagree Strongly). Total score range is 0-20 where lower score indicated better results.
At Baseline and after 12 weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Gum Health Analysis by Change From Baseline in Overall Mean Scores of Participant Responses to the Gum Comfort Questionnaire After 1, 4 and 8 Weeks
Time Frame: At Baseline and after 1 week, 4 weeks and 8 weeks
Gum comfort questionnaire was referred to assess the gum health of the denture wearer and to compare the ability of an experimental denture adhesive to provide self-perceived mucosal benefits compared to the use of no adhesive after 1, 4 and 8 weeks of product use. It was comprised of 5 questions- Q1: My gums feel comfortable when wearing my denture(s), Q2: I feel my gums are cushioned from the impact of chewing and biting; Q3: My gums do not feel sore at the end of the day; Q4: My gums are not irritated by trapped food particles under my denture(s); Q5: My gums do not feel tired at the end of the day. The participants recorded the response on scale of 0-4: 0-Agree Strongly, 1-Agree Somewhat, 3-Neither Agree or Disagree, 4= Disagree Strongly). Total score range is 0-20 where lower score indicated better results.
At Baseline and after 1 week, 4 weeks and 8 weeks
Gum Health Analysis by Change From Baseline in Mean Scores of Participant Responses to the Individual Questions on the Gum Comfort Questionnaire After 1, 4, 8 and 12 Weeks.
Time Frame: At Baseline and after 1 week, 4 weeks, 8 weeks and 12 weeks
Gum comfort questionnaire was referred to assess the gum health of the denture wearer and to compare the ability of an experimental denture adhesive to provide self-perceived mucosal benefits compared to the use of no adhesive after 1, 4, 8 and 12 weeks of product use. It was comprised of 5 questions- Q1: My gums feel comfortable when wearing my denture(s), Q2: I feel my gums are cushioned from the impact of chewing and biting; Q3: My gums do not feel sore at the end of the day; Q4: My gums are not irritated by trapped food particles under my denture(s); Q5: My gums do not feel tired at the end of the day. The participants recorded the response on scale of 0-4: 0-Agree Strongly, 1-Agree Somewhat, 3-Neither Agree or Disagree, 4= Disagree Strongly). Total score range is 0-20 where lower score indicated better results.
At Baseline and after 1 week, 4 weeks, 8 weeks and 12 weeks
Mucosal Health Analysis of Denture Bearing Tissues by Change From Baseline in Mucosal Score Assessment (MSA) After 1, 4, 8 and 12 Weeks
Time Frame: At Baseline and after 1 week, 4 weeks, 8 weeks and 12 weeks
MSA used by dentist to assess health of denture bearing tissues of participants across whole mouth on scale:1-4,1- normal appearance of gingiva,oral mucosa,2-mild inflammation(slight redness and/or hypertrophy/hyperplasia of gingiva and slight redness in some areas of palatal mucosa,including red spots indicating inflamed salivary duct orifices),3-moderate inflammation(marked redness and hypertrophy/hyperplasia of the gingiva, in large ares of palate, in oral mucosa, ulceration caused by denture, red and inflamed fibro-epithelial hyperplasia caused by denture),4-severe inflammation(severe redness and hypertrophy/hyperplasia of gingiva,spontaneous gingival bleeding, marked palatal granulations, inflamed oral mucosa areas).MSA was performed on denture-bearing tissues for either/both dentures across whole mouth and examiner recorded highest applicable score. Lower score indicated better results.
At Baseline and after 1 week, 4 weeks, 8 weeks and 12 weeks
Oral Health Related Quality of Life (OHrQoL) Analysis by Change From Baseline in Overall Mean Scores of Participant Responses to the Oral Health Impact Profile for Edentulous Patients (OHIP)-Edent Questionnaires After 1, 4, 8 and 12 Weeks
Time Frame: At Baseline and after 1 week, 4 weeks, 8 weeks and 12 weeks
OHIP-Edent questionnaire was used for the evaluation of OHrQoL. This questionnaire was comprised of 19 questions grouped into 6 functional domains and the participants responded on the scale of 0-4: 0-never, 1-rarely, 2-occasionally, 3-often and 4-very often. The functional domains are: domain 1- functional limitations (questions 1-3, score range 0-12), domain 2- physical pain (questions 4-7, score range 0-16), domain 3- psychological discomfort (questions 8-9, score range 0-8), domain 4- physical disability (questions 10-12, score range 0-12), domain 5- psychological disability (questions 13-14, score range 0-8) and domain 6- social disability (questions 15-19, score range 0-20). The overall score range is 0-76 where 0 is the best possible score. Lower scores represent a more favorable perception of participants OHrQoL.
At Baseline and after 1 week, 4 weeks, 8 weeks and 12 weeks
OHrQoL Analysis by Change From Baseline in Average Domain Scores of Participant Responses to the OHIP-Edent Questionnaires After 1, 4, 8 and 12 Weeks
Time Frame: At Baseline and after 1 week, 4 weeks, 8 weeks and 12 weeks
OHIP-Edent questionnaire was used for the evaluation of OHrQoL. This questionnaire was comprised of 19 questions grouped into 6 functional domains and the participants responded on the scale of 0-4: 0-never, 1-rarely, 2-occasionally, 3-often and 4-very often. The functional domains are: domain 1- functional limitations (questions 1-3, score range 0-12), domain 2- physical pain (questions 4-7, score range 0-16), domain 3- psychological discomfort (questions 8-9, score range 0-8), domain 4- physical disability (questions 10-12, score range 0-12), domain 5- psychological disability (questions 13-14, score range 0-8) and domain 6- social disability (questions 15-19, score range 0-20). The overall score range is 0-76 where 0 is the best possible score. Lower scores represent a more favorable perception of participants OHrQoL.
At Baseline and after 1 week, 4 weeks, 8 weeks and 12 weeks
OHrQoL Analysis by Change From Baseline in Overall Mean Scores of Participant Responses to the General Oral Health Assessment Index (GOHAI) Questionnaires After 1, 4, 8 and 12 Weeks
Time Frame: At Baseline and after 1 week, 4 weeks, 8 weeks and 12 weeks
GOHAI questionnaire was used for the evaluation of OHrQoL. It was comprised of 12 questions with 6 possible responses. The participants responded on the scale of 0-5: 0-always, 1-very often, 2-often, 3-sometimes, 4-seldom and 5-never. The functional domain of the questionnaire are as: domain 1: functional (questions 1-4, score range 0-20, participant's ability to eat, speak and swallow); domain 2: psychological (questions 6,7,9-11, score range 0-25, participant's concerns, relationships and appearance); domain 3- pain/ discomfort (questions 5,8,12, score range 0-15, participant's discomfort during chewing, sensitivity to hot/cold/sweets and use of medications to manage oral pain). The responses were scored on a 0 (always)-5 (never) scale for all questions except 3, 5 and 7 where the scoring is reversed, and thus the range of scores for the questionnaire is 0-60, where 60 is the best possible score. Higher score indicated better results.
At Baseline and after 1 week, 4 weeks, 8 weeks and 12 weeks
OHrQoL Analysis by Change From Baseline in Average Domain Scores of Participant Responses to the GOHAI Questionnaires After 1, 4, 8 and 12 Weeks
Time Frame: At Baseline and after 1 week, 4 weeks, 8 weeks and 12 weeks
GOHAI questionnaire was used for the evaluation of OHrQoL. It was comprised of 12 questions with 6 possible responses. The participants responded on the scale of 0-5: 0-always, 1-very often, 2-often, 3-sometimes, 4-seldom and 5-never. The functional domain of the questionnaire are as: domain 1: functional (questions 1-4, score range 0-20, participant's ability to eat, speak and swallow); domain 2: psychological (questions 6,7,9-11, score range 0-25, participant's concerns, relationships and appearance); domain 3- pain/ discomfort (questions 5,8,12, score range 0-15, participant's discomfort during chewing, sensitivity to hot/cold/sweets and use of medications to manage oral pain). The responses were scored on a 0 (always)-5 (never) scale for all questions except 3, 5 and 7 where the scoring is reversed, and thus the range of scores for the questionnaire is 0-60, where 60 is the best possible score. Higher score indicated better results.
At Baseline and after 1 week, 4 weeks, 8 weeks and 12 weeks
Mean Scores of Participant Responses to the Sensory Questionnaire at Week 4
Time Frame: At week 4
Sensory attributes of the adhesive was assessed by sensory questionnaire which was comprised of 6 questions; Q1: I feel the product has a smooth texture on my gums, Q2: I feel the product is gentle on my gums, Q3: I feel the product flavor soothes my gums, Q4: I feel the product flavor cools my gums, Q5: I feel the product is easy to apply, Q6: I feel less rubbing from my denture throughout the day when using this product. This questionnaire was only referred to participants randomized to the experimental adhesive group. The participants responded for all questions on the scale of 0-4: 0-agree strongly,1-agree somewhat, 2-neither agree or disagree, 3-disagree somewhat, 4-disagree strongly. The total score range is 0-24 where a low score indicated better results.
At week 4

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
GlaxoSmithKline

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
February 4, 2019

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 4, 2019

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
May 4, 2019

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
January 15, 2019

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 15, 2019

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
January 17, 2019

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 5, 2021

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 12, 2021

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2021

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 209510

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

IPD for this study is available via the Clinical Study Data Request site

IPD Sharing Time Frame

IPD is available via the Clinical Study Data Request site (copy the URL below to your browser)

IPD Sharing Access Criteria

Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Denture Retention

Clinical Trials on Experimental Denture Adhesive

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings